{"id":51731,"date":"2022-12-08T15:02:43","date_gmt":"2022-12-08T14:02:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/"},"modified":"2022-12-08T15:02:43","modified_gmt":"2022-12-08T14:02:43","slug":"fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/","title":{"rendered":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma"},"content":{"rendered":"
\n

\nImproving access to oncology therapies in the United States<\/b>\n<\/p>\n

LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi<\/a>–Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn\u00ae<\/sup>, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available immediately in the United Sates and is the newest addition to the company\u2019s injectable oncology medicine portfolio, the largest in U.S. health care.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cFresenius Kabi is committed to expanding access to high-quality, high-value oncology medicines,\u201d said John Ducker, president and CEO of Fresenius Kabi USA. \u201cWe are pleased to offer Pralatrexate in the United States and we intend to continue to bring new oncology medicines, including biosimilars, to U.S. patients.\u201d\n<\/p>\n

\nFresenius Kabi Pralatrexate Injection provides clinicians and patients with a generic treatment option for adult patients with relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available in two single-dose vial presentations: 20 mg\/1 mL and 40 mg\/2 mL.\n<\/p>\n

\nAbout Pralatrexate Injection<\/b>\n<\/p>\n

\nPralatrexate injection is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).\n<\/p>\n

\nThis indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\n<\/p>\n

\nImportant Safety Information<\/b>\n<\/p>\n

\nMyelosuppression: Monitor complete blood counts and omit and\/or reduce dose based on ANC and platelet count.\n<\/p>\n

\nMucositis: Monitor at least weekly. Omit and\/or reduce dose for grade 2 or higher mucositis.\n<\/p>\n

\nDermatologic reactions: Reactions, including fatal reactions, occurred and may be progressive and increase in severity with further treatment. Monitor closely and withhold or discontinue Pralatrexate injection based on severity.\n<\/p>\n

\nTumor lysis syndrome: Monitor patients who are increased risk and treat promptly.\n<\/p>\n

\nHepatic toxicity: Monitor for liver function tests. Omit until recovery, adjust or discontinue therapy based on severity.\n<\/p>\n

\nRisk of increased toxicity with renal impairment: Avoid Pralatrexate injection in patients with end stage renal disease with or without dialysis. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the Pralatrexate injection dose based on adverse reactions.\n<\/p>\n

\nEmbryo-fetal toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use an effective method of contraception.\n<\/p>\n

\nMost common adverse reactions (>35%) are mucositis, thrombocytopenia, nausea, and fatigue.\n<\/p>\n

\nTo report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800\u2010551\u20107176, option 5, or FDA at 1\u2010800\u2010FDA\u20101088 or <\/b>www.fda.gov\/medwatch<\/a><\/b><\/span>.<\/b>\n<\/p>\n

\nAvoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions.\n<\/p>\n

\nLactation: Advise not to breastfeed.\n<\/p>\n

\nThis Important Safety Information does not include all the information needed to use Pralatrexate Injection safely and effectively. Please see full prescribing information for Pralatrexate Injection at <\/b>www.fresenius-kabi.com\/us<\/a><\/b><\/span>.<\/b>\n<\/p>\n

\nAbout Fresenius Kabi<\/b>\n<\/p>\n

\nFresenius Kabi (www.fresenius-kabi.com\/us<\/a>) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company\u2019s products and services are used to help care for critically and chronically ill patients. The company\u2019s U.S. headquarters is in Lake Zurich, Illinois. The company\u2019s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com\/us\/join-us<\/a> and follow us on LinkedIn<\/a>.\n<\/p>\n

\n*Folotyn\u00ae<\/sup> is a registered trademark of Acrotech Biopharma.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact<\/b>
Joanie Clougherty (614) 717-5741
\n
joan.clougherty@fresenius-kabi.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Improving access to oncology therapies in the United States LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi–Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn\u00ae, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available immediately in the United Sates and is the newest addition to the company\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51731","6":"format-standard","7":"category-industry"},"yoast_head":"\nFresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Improving access to oncology therapies in the United States LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi–Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn\u00ae, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available immediately in the United Sates and is the newest addition to the company\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-08T14:02:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221208005257\/en\/1658970\/21\/Pralatrexate_Group.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma\",\"datePublished\":\"2022-12-08T14:02:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/\"},\"wordCount\":583,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005257\\\/en\\\/1658970\\\/21\\\/Pralatrexate_Group.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/\",\"name\":\"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005257\\\/en\\\/1658970\\\/21\\\/Pralatrexate_Group.jpg\",\"datePublished\":\"2022-12-08T14:02:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005257\\\/en\\\/1658970\\\/21\\\/Pralatrexate_Group.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221208005257\\\/en\\\/1658970\\\/21\\\/Pralatrexate_Group.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/","og_locale":"en_US","og_type":"article","og_title":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma - Pharma Trend","og_description":"Improving access to oncology therapies in the United States LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi–Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn\u00ae, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available immediately in the United Sates and is the newest addition to the company\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-08T14:02:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221208005257\/en\/1658970\/21\/Pralatrexate_Group.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","datePublished":"2022-12-08T14:02:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/"},"wordCount":583,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221208005257\/en\/1658970\/21\/Pralatrexate_Group.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/","url":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/","name":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221208005257\/en\/1658970\/21\/Pralatrexate_Group.jpg","datePublished":"2022-12-08T14:02:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221208005257\/en\/1658970\/21\/Pralatrexate_Group.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221208005257\/en\/1658970\/21\/Pralatrexate_Group.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-introduces-pralatrexate-injection-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51731"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51731\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}